Gene fusions that involve the neurotrophin tyrosine/tropomyosin receptor kinases 1, 2, and 3 genes (NTRK1, NTRK2, and NTRK3, which encode TRKA, TRKB, and TRKC proteins, respectively) result in constitutively active fusion proteins with an active TRK kinase domain that drives the development of cancer [1]. Here, NTRK2 is linked to cancer.